Ultragenyx's gene therapy helps control ammonia levels in late-stage study
Reuters03-12
Ultragenyx's gene therapy helps control ammonia levels in late-stage study
March 12 (Reuters) - Ultragenyx Pharmaceutical RARE.O said on Thursday its experimental gene therapy helped patients in a late-stage trial to better control ammonia levels linked to a rare inherited disorder.
(Reporting by Padmanabhan Ananthan in Bengaluru)
((Padmanabhan.Ananthan@thomsonreuters.com;))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments